Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286457 | 0.89 | MAPT (0.47) | MAPTALDH1A1TLR4MEN1KMT2A | |
| SCHEMBL19841984 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1CYP2D6TLR4MEN1 | |
| SCHEMBL9830385 | 0.80 | MAPT (0.49) | MAPTALDH1A1TLR4MEN1KMT2A | |
| SCHEMBL19841968 | 0.79 | ALDH1A1 (0.46) | MAPTALDH1A1CYP2D6TLR4MEN1 | |
| SCHEMBL23039821 | 0.78 | MAPT (0.43) | MAPTALDH1A1TLR4MEN1KMT2A | |
| SCHEMBL2470785 | 0.78 | TLR4 (0.51) | MAPTALDH1A1CYP2D6TLR4MEN1 | |
| SCHEMBL276016 | 0.78 | TLR4 (0.51) | MAPTALDH1A1CYP2D6TLR4MEN1 | |
| SCHEMBL19841982 | 0.77 | TLR4 (0.48) | MAPTALDH1A1CYP2D6TLR4MEN1 | |
| SCHEMBL7733726 | 0.76 | TLR4 (0.50) | MAPTALDH1A1CYP2D6TLR4MEN1 | |
| SCHEMBL7392059 | 0.76 | TLR4 (0.50) | MAPTALDH1A1CYP2D6TLR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-9884831-B2 | Azocane and azonane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | MAPT 3576/4885ALDH1A1 2044/4885CYP2D6 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.